Oncodoc
@anthonymjoshua.bsky.social
📤 142
📥 86
📝 0
reposted by
Oncodoc
Jia (Jenny) Liu MD PhD
9 months ago
🔗 :
ascopubs.org/doi/10.1200/...
🙏 for the wonderful collaboration and mentorship from many experts around the globe!
@anthonymjoshua.bsky.social
@oncocook.bsky.social
@weldeiry.bsky.social
@sarahblagden.bsky.social
@viveksubbiah.bsky.social
@oncoalert.bsky.social
@oncodaily.bsky.social
loading . . .
Accelerating the Future of Oncology Drug Development: The Role of Consortia in the Delivery of Precision Oncology Early Phase Clinical Trials
PURPOSEOver the past 15 years, the landscape of early phase clinical trials (EPCTs) has undergone a remarkable expansion in both quantity and intricacy. The proliferation of sites, trials, sponsors, a...
https://ascopubs.org/doi/10.1200/JCO-24-01534
1
6
2
reposted by
Oncodoc
Ravi Madan
10 months ago
Since
#EMBARK
data there is a need to define high risk
#BCR
#ProstateCancer
Best data I have seen comes from @HopkinsMedicine team Risk of mets at 5 years is only 26% for
#PSA
DT 6-9 months. Significantly lower risk than DT 3-6 mos or DT under 3 mos
ascopubs.org/doi/10.1200/...
0
6
3
reposted by
Oncodoc
John Ebos
10 months ago
Review: The present and future of bispecific antibodies for cancer therapy
loading . . .
The present and future of bispecific antibodies for cancer therapy - Nature Reviews Drug Discovery
Bispecific antibodies (bsAbs) can mediate therapeutic effects beyond those of natural monospecific antibodies. This Review provides an overview of recent developments in the field of bsAbs for cancer ...
https://www.nature.com/articles/s41573-024-00896-6
1
13
8
reposted by
Oncodoc
The Advanced Prostate Cancer Consensus Conference
10 months ago
Elucidating acquired PARP inh resistance
sciencedirect.com/science/arti...
Highlights emergence of resistance in met CR
#ProstateCancer
tx w/ PARP inh💊, particularly in BRCA2 & PALB2 mutations🧬
@drnataliagandur.bsky.social
@barbaramelao.bsky.social
@achoud72.bsky.social
@yukselurun.bsky.social
loading . . .
Elucidating acquired PARP inhibitor resistance in advanced prostate cancer
PARP inhibition (PARPi) has anti-tumor activity against castration-resistant prostate cancer (CRPC) with homologous recombination repair (HRR) defects…
https://sciencedirect.com/science/article/pii/S1535610824004033
0
22
8
reposted by
Oncodoc
Space
11 months ago
How the Andromeda galaxy would look from Earth if it were brighter
546
47323
2628
you reached the end!!
feeds!
log in
